Cell cycle re-entry of senescent breast cancer cells after CDK4/6 inhibition (CDK4/6i) constitutes a major source of disease ...

Among the many promising advances in breast cancer treatment in recent years are CDK4/6 inhibitors. These are targeted drugs that can be used for women with a common type of breast cancer ...

CEO John Houston emphasized that Arvinas is nearing key milestones, including the first Phase 3 topline data for vepdegestrant (vepdeg) from the VERITAC-2 trial expected in Q1 2025. He noted that this ...

Cyclin-dependent kinases 4 and 6 (CDK4/6) are crucial cell cycle regulators and have become significant targets in breast cancer therapy. Current CDK4/6 inhibitors, while effective, often come with ...

“We found that pharmacologically targeting a single kinase, CDK2, can trigger two distinct cellular responses depending on the tumor type,” said Vishnu Kumarasamy, PhD, first author on the new study ...

One of the most important launches for Novartis in recent years is off with a bang. | One of the most important launches for ...

Paolo Tarantino, MD, PhD, discusses the approval of the oral therapy elacestrant for patients with estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer with ESR1 mutations.

MDM2 turnover and expression of ATRX determine the choice between quiescence and senescence in response to CDK4 inhibition. Oncotarget 10: 8226-43, 2015 Abbas Manji G, Singer S, Koff A, and Schwartz ...